Hirokazu Nagawa

Hirokazu Nagawa

Auto-generated profile, based on publicly available information

Hirokazu Nagawa

Department of Surgical Oncology, Faculty of Medical Sciences, the University of Tokyo, Tokyo 113-8655, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KSKazuhito Sasaki
Kazuhito Sasaki
NTNelson H Tsuno
Nelson H Tsuno
ESEiji Sunami
Eiji Sunami
GTGiichiro Tsurita
Giichiro Tsurita
KKKazushige Kawai
Kazushige Kawai
HNHirokazu Nagawa
Hirokazu Nagawa
Chloroquine (CQ), the worldwide used anti-malarial drug, has recently being focused as a potential anti-cancer agent as well as a chemosensitizer when used in combination with anti-cancer drugs. It has been shown to inhibit cell growth and/or to induce cell death in various types of cancer. 5-Fluorouracil (5-FU) is the chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-FU develops through various mechanisms. Here, we focused on the combination of CQ as a mechanism to potentiate the inhibitory effect of 5-FU on human colon cancer cells. HT-29 cells were treated with CQ and/or 5-FU, and their proliferative ability, apoptosis and autophagy induction effects, and the affection of the cell cycle were evaluated. The proliferative ability of HT-29 was analyzed by the MTS assay. Apoptosis was quantified by flow-cytometry after double-staining of the cells with AnnexinV/PI. The cell cycle was evaluated by flow-cytometry after staining of cells with PI. Autophagy was quantified by flow-cytometry and Western blot analysis. Finally, to evaluate the fate of the cells treated with CQ and/or 5-FU, the colony formation assay was performed. 5-FU inhibited the proliferative activity of HT-29 cells, which was mostly dependent on the arrest of the cells to the G0/G1-phase but also partially on apoptosis induction, and the effect was potentiated by CQ pre-treatment. The potentiation of the inhibitory effect of 5-FU by CQ was dependent on the increase of p21Cip1 and p27Kip1 and the decrease of CDK2. Since CQ is reported to inhibit autophagy, the catabolic process necessary for cell survival under conditions of cell starvation or stress, which is induced by cancer cells as a protective mechanism against chemotherapeutic agents, we also analyzed the induction of autophagy in HT-29. HT-29 induced autophagy in response to 5-FU, and CQ inhibited this induction, a possible mechanism of the potentiation of the anti-cancer effect of 5-FU. Our findings suggest that the combination therapy with CQ should be a novel therapeutic modality to improve efficacy of 5-FU-based chemotherapy, possibly by inhibiting autophagy-dependent resistance to chemotherapy.

3 June 2010 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
JKJoji Kitayama
Joji Kitayama
KYKoji Yasuda
Koji Yasuda
KKKazushige Kawai
Kazushige Kawai
ESEiji Sunami
Eiji Sunami
HNHirokazu Nagawa
Hirokazu Nagawa
Although neoadjuvant chemoradiotherapy (CRT) is the standard treatment for advanced rectal cancer (RC), markers to predict the treatment response have not been fully established. In 73 patients with advanced RC who underwent CRT in a neoadjuvant setting, we retrospectively examined the associations between the clinical effects of CRT and blood cell counts before and after CRT. Clinical or pathological complete response (CR) was observed in 10 (14%) cases. The CR rate correlated significantly with the size and the circumferential extent of the tumor. Hemoglobin level, white blood cell (WBC) count and platelet count before CRT did not show a significant difference between CR and non-CR cases. Interestingly, however, lymphocyte ratio in WBC was significantly higher (p = 0.020), while neutrophil ratio tended to be lower (p = 0.099), in CR cases, which was shown to be an independent association by multivariate analysis. When all the blood data obtained in the entire treatment period were evaluated, circulating lymphocyte count was most markedly decreased in the CRT period and gradually recovered by the time of surgery, while the numbers of neutrophils and monocytes were comparatively stable. Moreover, the lymphocyte percentage in samples obtained from CR patients was maintained at a relatively higher level than that from non-CR patients. Since tumor shrinkage is known to be dependent not only on the characteristics of tumor cells but also on various host conditions, our data raise the possibility that a lymphocyte-mediated immune reaction may have a positive role in achieving complete eradication of tumor cells. Maintenance of circulating lymphocyte number may improve the response to CRT in rectal cancer.

1 June 2006 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Hiroharu YamashitaHiroharu Yamashita
Hiroharu Yamashita
JKJoji Kitayama
Joji Kitayama
NKNobuko Kanno
Nobuko Kanno
YYYutaka Yatomi
Yutaka Yatomi
HNHirokazu Nagawa
Hirokazu Nagawa
Abnormal hemostasis in cancer patients has previously been described, however the correlation between the plasma fibrinogen level and cancer metastasis and prognosis has not been reported in a large-scale clinical study. Preoperative plasma fibrinogen levels were retrospectively examined in 405 patients who underwent surgery for advanced gastric cancer. The association of fibrinogen levels with clinical/pathological findings and clinical outcome was evaluated. There was a positive correlation between plasma fibrinogen levels and the depth of invasion (p < 0.05). Hyperfibrinogenemia (>310 mg/dl) was independently associated with lymph node (Odds Ratio; 2.342, P = 0.0032) and liver (Odds Ratio; 2.933, P = 0.0147) metastasis, not with peritoneal metastasis in this series. Patients with hyperfibrinogenemia showed worse clinical outcome in T2 gastric cancer, however, there was no correlation of plasma fibrinogen level with prognosis in T3/T4 gastric cancer. Our results might support the idea that hyperfibrinogenemia can augment lymphatic and hematogeneous metastasis of advanced gastric cancer, which is major determinant of the prognosis in T2 gastric cancer. Therefore, in the situation without peritoneal involvement, hyperfibrinogenemia is a useful biomarker to predict the possible metastasis and worse clinical outcome in T2 gastric cancer.

1 April 2003
Verified
Journal Article
Closed access
DSDai Shida
Dai Shida
JKJoji Kitayama
Joji Kitayama
HYHironori Yamaguchi
Hironori Yamaguchi
YOYurai Okaji
Yurai Okaji
NTNelson Hirokazu Tsuno
Nelson Hirokazu Tsuno
HNHirokazu Nagawa
Hirokazu Nagawa

15 February 1999 in Cancer
Verified
Journal Article
Open access
PDF file
TOTakuya Osada
Takuya Osada
MSMichiie Sakamoto
Michiie Sakamoto
HNHirokazu Nagawa
Hirokazu Nagawa
JYJunji Yamamoto
Junji Yamamoto
YMYoshihiro Matsuno
Yoshihiro Matsuno
SHSetsuo Hirohashi
Setsuo Hirohashi
BACKGROUND The authors previously reported increased ubiquitin (Ub) immunoreactivity in hepatocellular carcinomas (HCCs) and suggested a possible correlation between changes in ubiquitinated protein levels and multistep hepatocarcinogenesis. The current study was performed to identify one of these ubiquitinated proteins (42 kDa) and to analyze the clinical significance of its accumulation. METHODS The protein was purified using two‐dimensional gel electrophoresis and identified by amino acid sequence analysis. The authors studied the expression of this protein in 101 HCCs and 23 precancerous lesions by immunohistochemical methods and in 26 HCCs by immunoblot analysis. A survival analysis was performed on patients with advanced HCC using the Kaplan–Meier method with approximate chi‐square statistics for the log rank test. RESULTS The target protein for ubiquitination was identified as glutamine synthetase (GS). Accumulation of GS was found in 19 of 49 advanced HCCs (38.8%) by immunohistochemical methods and in 9 of 16 (56.3%) by immunoblot analysis, whereas the frequency was much lower in early HCCs (12.9% and 33.3%, respectively) and precancerous lesions (4.3% by immunostaining). In the Ub immunoblot analysis of strongly GS positive specimens, an intense 42‐kDa ubiquitinated band was observed. Nine of 21 (42.9%) nodule‐in‐nodule type HCCs showed a GS positive, high‐grade component within a GS negative, low‐grade component, indicating the acquisition of GS expression during progression. Among 23 patients with a single advanced HCC nodule, the relapse free survival time was significantly shorter in the GS positive group than in the GS negative group. CONCLUSIONS The results of this study demonstrate the acquisition of GS expression during hepatocarcinogenesis and the possible regulation of GS enzyme activity by a Ub‐dependent proteolytic system. Moreover, GS might play a significant role in promoting the metastatic potential of HCC. Cancer 1999;85:819–31. © 1999 American Cancer Society.

1 July 1999 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MNMarcelo E. Nita
Marcelo E. Nita
HNHirokazu Nagawa
Hirokazu Nagawa
OTOsamu Tominaga
Osamu Tominaga
NTNelson Tsuno
Nelson Tsuno
KHKenji Hatano
Kenji Hatano
TMTetsuichiro Muto
Tetsuichiro Muto